Leerink Partnrs Issues Pessimistic Outlook for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings per share of ($0.66) for the year, down from their prior estimate of ($0.44). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at ($0.45) EPS.

Other equities research analysts have also issued research reports about the company. Wedbush dropped their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $5.64 on Friday. The business’s 50 day simple moving average is $6.62 and its 200 day simple moving average is $7.50. Voyager Therapeutics has a 52-week low of $5.59 and a 52-week high of $11.72. The firm has a market cap of $307.55 million, a PE ratio of 7.94 and a beta of 0.89.

Insider Buying and Selling

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its holdings in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares during the period. Victory Capital Management Inc. lifted its holdings in Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares during the period. SummerHaven Investment Management LLC lifted its holdings in Voyager Therapeutics by 2.5% during the second quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after acquiring an additional 1,921 shares during the period. Hunter Perkins Capital Management LLC lifted its holdings in Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after acquiring an additional 2,025 shares during the period. Finally, Empowered Funds LLC raised its stake in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after buying an additional 2,278 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.